Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
RECURSION PHARMACEUTICALS, INC. | Chief Financial Officer | Class A Common Stock | 842K | $4.29M | $5.10 | Apr 1, 2025 | Direct |
RECURSION PHARMACEUTICALS, INC. | Chief Financial Officer | Stock Option (Right to Buy) | 290K | Apr 1, 2025 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
RXRX | RECURSION PHARMACEUTICALS, INC. | Apr 1, 2025 | 1 | -$135K | 4 | Apr 3, 2025 | Chief Financial Officer |
RXRX | RECURSION PHARMACEUTICALS, INC. | Mar 17, 2025 | 1 | -$48.3K | 4 | Mar 19, 2025 | Chief Financial Officer |
RXRX | RECURSION PHARMACEUTICALS, INC. | Feb 18, 2025 | 1 | -$116K | 4 | Feb 20, 2025 | Chief Financial Officer |
RXRX | RECURSION PHARMACEUTICALS, INC. | Feb 3, 2025 | 4 | -$47.4K | 4 | Feb 5, 2025 | Chief Financial Officer |
RXRX | RECURSION PHARMACEUTICALS, INC. | Dec 19, 2024 | 2 | $0 | 4 | Dec 20, 2024 | Chief Financial Officer |
RXRX | RECURSION PHARMACEUTICALS, INC. | Dec 16, 2024 | 2 | -$144K | 4 | Dec 18, 2024 | Chief Financial Officer |
RXRX | RECURSION PHARMACEUTICALS, INC. | Nov 20, 2024 | 0 | $0 | 3 | Dec 2, 2024 | Chief Financial Officer |